2 recruiting, 1 temporarily not available. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
Follow Arumakimig: new trials by email Literature Review of Arumakimig trials Research Report on Arumakimig
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period Arumakimig, Placebo, Oral glucocorticoids - VEXAS Syndrome | Phase 2 | Recruiting | Novartis Pharmaceuticals | 120 | 2026-10-30 | 2026-10-13 |
| A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease MAS825 - Still´s Disease | Phase 2 | Recruiting | Novartis Pharmaceuticals | 30 | 2025-11-03 | 2026-09-25 |
| Managed Access Programs for MAS825, Arumakimig Arumakimig - Still's Disease, Including SJIA and AOSD, With MAS or ILD Complications | Temporarily not available | Novartis Pharmaceuticals | 2026-10-22 |
Arthritis, Juvenile (2) · Arthralgia (1) · Arthritis (1) · VEXAS syndrome (1)
Canada (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Netherlands (1) · Spain (1) · Turkey (Türkiye) (1) · United States (1)